ZNF282 Inhibitors
Chemical inhibitors of ZNF282 can modulate the protein's function by targeting various signaling pathways and enzymatic activities that are crucial for its regulatory role in transcription. Staurosporine, for example, acts as a protein kinase inhibitor, potentially impeding the phosphorylation states of proteins that interact with ZNF282, thereby altering its activity. Similarly, LY294002 and Wortmannin, both inhibitors of PI3K, can obstruct the PI3K signaling cascade, which may be essential for ZNF282-mediated transcriptional events. This blockade hampers the necessary signaling events that ZNF282 relies on to exert its effect on gene expression. Rapamycin, as an mTOR inhibitor, can reduce the transcriptional activity of genes where ZNF282 is a critical component by limiting mTOR's role in gene regulation. PD98059 and U0126, by inhibiting MEK1/2, can decrease the activation of the MAPK/ERK pathway, a potential requisite for ZNF282's involvement in transcriptional regulation.
Furthermore, SP600125's inhibition of JNK can lead to reduced functional activity of ZNF282 by diminishing the activation of JNK-dependent transcription factors and their co-regulators. Bisindolylmaleimide I and Chelerythrine, both inhibitors of PKC, can disrupt the phosphorylation and thus the function of proteins that associate with ZNF282 in the regulation of gene transcription. SB203580 specifically targets p38 MAPK, and by impeding this kinase, it can influence the regulatory effects of ZNF282 on transcription. Go 6983, another PKC inhibitor, can prevent activation of PKC isoforms, leading to a decrease in the phosphorylation of ZNF282's transcriptional partners. Lastly, Triciribine, by specifically inhibiting the AKT pathway, can disrupt AKT-dependent interactions that are important for ZNF282's function, leading to an overall decrease in its regulatory influence on gene expression.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a known protein kinase inhibitor. As ZNF282 has been reported to interact with transcriptional machinery that could be phosphorylation-dependent, staurosporine may inhibit this interaction by preventing the phosphorylation of proteins that associate with ZNF282, thereby inhibiting ZNF282's function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K. ZNF282 is involved in transcriptional regulation that can be PI3K pathway-dependent. Inhibition of PI3K by LY294002 can disrupt signal transduction processes necessary for ZNF282 to exert its regulatory functions, leading to its functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a kinase that can control the transcription of certain genes. mTOR inhibition by rapamycin may reduce the transcriptional activity where ZNF282 is a necessary component, thus functionally inhibiting ZNF282's regulatory role. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which lies upstream of ERK in the MAPK pathway. By inhibiting MEK, PD98059 can decrease ERK activity, which could be necessary for the transcriptional regulation by ZNF282, leading to its functional inhibition. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, which are crucial for the MAPK/ERK pathway. By inhibiting this pathway, U0126 can prevent the phosphorylation of substrates that might be co-regulators with ZNF282, thereby inhibiting the functional capacity of ZNF282. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which can affect transcription factors and their co-regulators. Inhibition of JNK activity by SP600125 can lead to a downstream decrease in the functional activity of ZNF282 by disrupting the activation of transcriptional programs that ZNF282 is part of. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, similar to LY294002. Inhibition of PI3K by wortmannin can lead to a blockade of the signaling events necessary for ZNF282 to exert its effect on gene transcription, functionally inhibiting ZNF282. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a PKC inhibitor. Since PKC can phosphorylate transcriptional co-regulators, inhibition of PKC by Bisindolylmaleimide I can reduce the co-regulatory function of proteins that work with ZNF282, leading to its functional inhibition. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $90.00 $317.00 | 17 | |
Chelerythrine is a potent inhibitor of PKC. By inhibiting PKC, Chelerythrine can disrupt the phosphorylation and thus the activity of transcriptional co-regulators of ZNF282, resulting in the inhibition of ZNF282's function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. The p38 MAPK pathway may be involved in the regulation of transcription factors and co-regulators associated with ZNF282's function. Inhibition of p38 MAPK can thus inhibit the functional activity of ZNF282. | ||||||